05.01.18
Charles River Laboratories has expanded its early discovery screening capabilities with access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Charles River has also expanded its pharmacokinetic (PK) capabilities at sites in both San Francisco and Hertogenbosch, The Netherlands.
Early screening provides important insight into a compound’s underlying biology, and streamlined HT-ADME and PK technologies are essential components to identifying promising candidates early in the drug discovery process. ADDA system is a high-speed autosampler designed for drug discovery that provides ADME discovery scientists with a fast sample delivery platform for liquid chromatography/mass spectrometry (LC/MS).
Therapeutic-area-agnostic PK services support drug discovery efforts from the initial PK screening of compounds and lead optimization to late-stage candidate nomination and Investigational New Drug-enabling studies.
“In early discovery research, screening is an essential component of any successful program. With access to industry-leading technologies, we’re able to provide our clients strategic guidance, ultimately working toward accelerating their programs.” said Birgit Girshick, corporate executive vice president, Discovery and Safety Assessment, Charles River.
Early screening provides important insight into a compound’s underlying biology, and streamlined HT-ADME and PK technologies are essential components to identifying promising candidates early in the drug discovery process. ADDA system is a high-speed autosampler designed for drug discovery that provides ADME discovery scientists with a fast sample delivery platform for liquid chromatography/mass spectrometry (LC/MS).
Therapeutic-area-agnostic PK services support drug discovery efforts from the initial PK screening of compounds and lead optimization to late-stage candidate nomination and Investigational New Drug-enabling studies.
“In early discovery research, screening is an essential component of any successful program. With access to industry-leading technologies, we’re able to provide our clients strategic guidance, ultimately working toward accelerating their programs.” said Birgit Girshick, corporate executive vice president, Discovery and Safety Assessment, Charles River.